Adalimumab blocks TNF receptors and modulates leukocyte migration. Reduces inflammation markers and improves blood counts. Shows significant improvement in quality of life and physical function
AS is a rare inflammatory disease causing spine pain and stiffness. Symptoms typically appear in 20-30 year olds, starting in lower back. No cure exists, treatments include medication, exercise, and physical therapy. Most patients have HLA-B27 antigen, likely genetic and environmental factors
BASDAI evaluates disease activity in Ankylosing Spondylitis. Index assesses six dimensions: fatigue, spinal pain, joint pain, tenderness, morning stiffness. Each dimension scored on 1-10 scale, morning stiffness duration scored 0-10
HLA-B27 association discovered in 1972 with ankylosing spondylitis. 19-88% of uveitis patients have HLA-B27 phenotype. HLA-B27 prevalence varies by population: 6.1% in US, 7.5% in Whites
Brand name Cimzia, manufactured by UCB. Approved for Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Listed on WHO's Essential Medicines
AS is a type of arthritis affecting spine joints, typically between pelvis and spine. Affects 0.1-0.8% of population, with peak onset between 20-30 years. More common in Northern Europeans, least in Afro-Caribbean descent